GRI Bio Inc (GRI)

[glenn1919]

GRI.................................https://stockcharts.com/h-sc/ui?s=GRI&p=W&b=5&g=0&id=p86431144783

[Gizzer211]

It's just his opinion

[AngusPorter]

And what is that? Why not share? 

[Ratface]

Obviously yes

[AngusPorter]

Well do you know something? 

[Ratface]

Funny reading all these posts nobody knows shit

[AngusPorter]

Keeps going down, what do you think the bottom is going to be? 

[Mr. White]

I agree, the Nov. Earnings will be on the radar.

[zj3001]

Anyone seeing this chart? Looks like it's going to rip to me. Just needs to hold .96/.97 right? 

[Ratface]

I agree hold onto your shares, we still have a nice road coming ahead.

[zj3001]

StockTwits bears are attacking it hard to load up. 

Using a prior offering agreement in February to scare people. 

The original agreement was for HC to purchase warrrants at 14.3 a share. However, you need to account for the reverse split of 13-1 in July (or June?). The warrants then became exercisable at $1.

New float will be 3.69m 
Adding $800k cash to balance sheets. 

Over reaction and still undervalued. 
Waiting for the chart pumpers to come in this afternoon to run it up. 

Just my 2 cents.

[Mr. White]

Crap. WTF

[Ratface]

Here

[Ratface]

Yikes

[Mr. White]

Me ZZZZZZzzzzz missed some money for sleeping in....damn it.

[Mr. White]

I see. All down..down...down...except, chart aside...they have a promising arthritis drug and a Japanese patent rights. These types of things can't be viewed on a chart. Notice pharmacy stocks at the .50 range going straight up? DRUG was .90 when I found it. GRI was .60 when I found it. Institutional intrest...or deep pockets, but serious interest 🤔

[Mr. White]

News after hour Could be something for tomorrow pre market,
GRI Bio Announces Exercise of Warrants
October 21 2024 - 5:35PM
🤔

[zj3001]

What’s thoughts on AH activity?

[Ratface]

Chomp chomp chomp

[zj3001]

Again.

[zj3001]

Halted

[glenn1919]

GRI...................................https://stockcharts.com/h-sc/ui?s=GRI&p=W&b=5&g=0&id=p86431144783

[tw0122]

Assuming Going past $2 one more round for some quick gains for latecomers

[tw0122]

Cashed out on SYTA also your not too late for AMC it’s ready for 100% pump likely but no guarantees

[zj3001]

Small 6am cst sell off from those that slept in. Headed north! Extremely undervalued market cap.

[TheFinalCD]

GM NICE EARLY ALERTS

.87 + 50%

$GRI $0.70 - Current company valuation is less than $3 mln despite ~$6 mln cash on hand and drugs in development stages. Remember they also have library of 500+ proprietary compounds that can further enrich their drug discovery pipeline.
Recent acquisitions in IPF (Idiopathic… pic.twitter.com/CbmG68QKA8

— SuperDuper Investor (@SuperDuperInvst) October 20, 2024

[tw0122]

$2 + 240%

[tw0122]

GRI 1.62 + 180% flipping out now gains secured

[tw0122]

GRI up 150% now

[tw0122]

GRI 1.44 + 150%

[tw0122]

$1.13 + 96%

[tw0122]

.87 + 50%

[zj3001]

Top 10 watchers on StockTwits now.

[zj3001]

Additional data added here…

$GRI is very transparent on their goal here. Just read between the lines, Pharma partner or Buyout incoming!

✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.

b2idigital.com/gri-bio

✅ News last week stating positive phase 2 data has been demonstrated, study on going.

gribio.com/gri-bio-presen…

✅ Phase 2 expected to be done this year (2024).

clinicaltrials.gov/study/NCT06331…

✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”

s3.amazonaws.com/sec.irpass.cc/…

✅Nasdaq compliance due by March 2025.

✅Executives have a track record of building pharma drugs/companies and selling them off. Their profiles discuss deal markers, IP protection, acquisition/mergers.

✅2.93m shares OS

✅ GRI Bio’s key executives own the following amounts of shares:

Walter Marc Hertz, CEO, holds approximately 385,510 shares.

Albert Agro, Chief Medical Officer, owns around 172,189 shares.

Vipin Chaturvedi, Chief Scientific Officer, also owns 172,189 shares.

Leanne Kelly, Chief Financial Officer, holds 83,333 shares.

Grok has this info for insiders

Based on the latest available data up to October 19, 2024, GRI Bio, Inc. (GRI) is largely owned by insiders,

- **Joseph E. Payne** owns **29.42%** of the company, making him the largest individual shareholder with 861,250 shares.
- **Arcturus Therapeutics Holdings Inc** holds **28.82%**.
- **Walter Marc Hertz** has **13.17%**.
- **Ofir Levi** owns **6.72%**.
- **Albert Agro** and **Vipin Chaturvedi** each own **5.88%**.
- **Richard Ammer** and **Pharma Gmbh Salmon** each hold **1.61%**.

[zj3001]

Things to note that I posted on X and ST.

✅Company stated earlier this year that it will have a partner or implied buyout when positive Phase2 verified proof of concept.

✅ News last week stating positive phase 2 data has been demonstrated, study on going.

https://gribio.com/gri-bio-presents-positive-preclinical-data-demonstrating-gri-0621s-ability-to-inhibit-invariant-natural-killer-t-inkt-cell-activity-and-reduce-important-inflammatory-and-fibrotic-drivers-in-idiopa/

✅ Phase 2 expected to be done this year (2024).

https://clinicaltrials.gov/study/NCT06331624?spons=GRI%20Bio%20Operations,%20Inc.&rank=1

✅ 10-Q 8/14/24, Page 9, “Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.”

https://s3.amazonaws.com/sec.irpass.cc/2647/0001824293-24-000105.htm



✅Nasdaq compliance due by March 2025.

[zj3001]

$GRI

$PLRX appears to be working on the same IPF treatment as GRI. Both in phase2a. GRI is much further along and will be done this year yet. However, PLRX has a market cap of over $900m and 60m shares!

Both basically have this treatment as their only drug in the pipeline.

If you remove $500m in plrx “assets” from market cap, GRI should be at $400m mc.


$400m mc / 2.93m shares = $136/share!

[zj3001]

Yea, this is nuts. Lol
Out of all the runners the last few weeks, this one has to be tightest if true. That’s less than 205k shares

[Gizzer211]

Maybe it will pull a DRUG move

[zj3001]

Is there really only 2.93m shares and just over 93% is held by insiders?

How is this not going to rip to $5-20?

[mining101]

Big times ahead

[pennyonfire]

In GRI. Looks like big bounce coming

[Mdrea]

GRI, Let's get this moving up.

[tw0122]

RI Bio Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Source: GlobeNewswire Inc.

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the presentation of positive preclinical data demonstrating its lead program GRI-0621 reduces important inflammatory and fibrotic drivers in Idiopathic Pulmonary Fibrosis (IPF).
The poster titled, “Involvement of Type 1 Invariant Natural Killer T Cells in Driving Lung Fibrosis,” was presented by Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio highlighting results of an analysis of bronchoalveolar lavage (BAL) fluid from IPF patients and GRI-0621 in a treatment model of pulmonary fibrosis was presented at the 22nd International Colloquium on Lung and Airway Fibrosis (ICLAF 2024) being held October 12-16, 2024 in Athens, Greece.

Marc Hertz, PhD, Chief Executive Officer of GRI Bio, commented, “We continue to believe in our therapeutic targets, and this preclinical data provides further helpful insight into the effects of targeting the inhibition of iNKT cell activity in later stages of a preclinical model of IPF. We believe GRI-0621 has the potential to provide significant benefit to IPF patients and we remain focused on its advancement toward interim data and topline data from our Phase 2a biomarker study in the coming quarters.”

Key Highlights

IPF patients had increased expression in whole BAL pellets of pro-fibrotic factors as Collagen 1-a1, osteopontin and TGF-ß, as assessed by qPCR.
Researchers detected an increase in IFN-? producing NKT cells in IPF, compared to controls and confirmed iNKT cell phenotype in a second cohort, using an antibody against Va24-Ja18 of the iNKT TCR.
GRI-0621 treatment, administered during the fibrotic phase of the bleomycin model of pulmonary fibrosis, improved a majority of inflammatory, fibrotic and pathological features including a reduction in lung injury, myofibroblast activity, collagen deposition and fibrosis.
IPF is a rare chronic progressive pulmonary disease with abnormal scarring of the lung blocking the movement of oxygen into the bloodstream. The architectural destruction of the lung results in breathlessness, significant decline in quality of life and an average untreated survival of 3.5 years from diagnosis. Currently available treatments for IPF are limited with only two approved drugs that come with significant side-effects, limited compliance and no impact on survival1.

GRI Bio is currently advancing its lead program GRI-0621, a small molecule RAR-ß? dual agonist candidate that inhibits the activity of human iNKT cells, in a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study for the treatment of IPF. Interim data from the Phase 2a biomarker study is expected in the fourth quarter of 2024 and topline results are expected in the first quarter of 2025.

[mining101]

Nice

[Awl416]

Yawn…

[tw0122]

GRI .52 cashing all out resistance at .58

[tw0122]

GRI .41 +’18% 09:24 AM EDT, 09/30/2024 (MT Newswires) -- GRI Bio (GRI) said Monday it has received a "decision to grant" notice from Japan's Patent Office for a patent application covering the use of natural killer T cell modulators to prevent and treat inflammatory diseases.

The patent covers claims, which include compositions and methods, for modulating type 2 and/or type 1 invariant natural killer T cells to prevent and treat the conditions, the company said.

[mining101]

Hui

[mining101]

Breakout - big news ahead?!

[tw0122]

3 days with volume.. Diluted garbage should at least see .72 before the next dump ..how much more deadbeat merciless dilution before the next reverse split